---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-274220"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:22:19.651392+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annexon posts Q3 net loss $54.9M, extends cash runway to late Q1 2027; GBS MAA filing on track for Jan 2026

## Summary
- Net loss $54.9M ($0.37 per share) in Q3 2025, compared to net loss $34.8M ($0.25 per share) in Q3 2024.
- R&D expenses $49.7M, up from $30.1M, driven by Phase 3 ARCHER II trial and global GBS regulatory filings.
- Cash and equivalents $188.7M as of Sep 30, 2025; operations funded into late Q1 2027 through key milestones.
- Tanruprubart (ANX005) GBS MAA submission on track for Jan 2026; FDA discussions on BLA generalizability package ongoing.
- Vonaprument (ANX007) Phase 3 ARCHER II trial enrolled 659 GA patients; topline data expected second half 2026.

## SEC filing metadata
- accession: 0001193125-25-274220
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/0001193125-25-274220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312525274220/annx-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-274220
- JSON: https://secwatch.observer/filing/0001193125-25-274220.json
- Plain text: https://secwatch.observer/filing/0001193125-25-274220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.